# Antonio M. Gotto

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/antonio-m-gotto/

## Facts

| Field | Value |
| --- | --- |
| Citations | 84,513 |
| Field | Lipoproteins and Cardiovascular Health |
| h-index | 104 |
| i10-index | 466 |
| Last Known Institution | Cornell University |
| OpenAlex ID | https://openalex.org/A5068202304 |
| ORCID iD | https://orcid.org/0000-0001-8076-6783 |
| Works | 869 |

## Researcher papers

- [K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification](https://scholariq.org/papers/k-doqi-clinical-practice-guidelines-for-chronic-kidney-disease-evaluation/)
- [K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease](https://scholariq.org/papers/k-doqi-clinical-practice-guidelines-for-bone-metabolism-and-disease-in-chronic/)
- [Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials](https://scholariq.org/papers/statins-and-risk-of-incident-diabetes-a-collaborative-meta-analysis-of/)
- [Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins](https://scholariq.org/papers/association-of-ldl-cholesterol-non-hdl-cholesterol-and-apolipoprotein-b-levels/)
- [The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials](https://scholariq.org/papers/the-benefits-of-statins-in-people-without-established-cardiovascular-disease-but/)
- [Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials](https://scholariq.org/papers/efficacy-and-safety-of-statin-therapy-in-older-people-a-meta-analysis-of/)
- [HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials](https://scholariq.org/papers/hmg-coenzyme-a-reductase-inhibition-type-2-diabetes-and-bodyweight-evidence-from/)
- [Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events](https://scholariq.org/papers/very-low-levels-of-atherogenic-lipoproteins-and-the-risk-for-cardiovascular/)

## Researcher topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Cholesterol and Lipid Metabolism](https://scholariq.org/topics/cholesterol-and-lipid-metabolism/)
- [Peroxisome Proliferator-Activated Receptors](https://scholariq.org/topics/peroxisome-proliferator-activated-receptors/)

## Researcher university

- [Cornell University](https://scholariq.org/institutions/cornell-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.